BYG4lab to Acquire Finbiosoft with Support from Keensight Capital
March 14, 2024
BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.
- Buyers
- BYG4lab, Keensight Capital
- Targets
- Finbiosoft
- Platforms
- BYG4lab
- Industry
- Software
- Location
- Uusimaa, Finland
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Keensight Capital Acquires Majority Stake in BYG4lab
July 22, 2022
Software
Keensight Capital has acquired a majority stake in BYG4lab, a France-headquartered provider of data management software for medical laboratories. The PE firm will support BYG4lab's international expansion (Europe and North America), product diversification and accelerated growth both organically and via acquisitions.
-
Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners
December 20, 2022
Software
Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.
-
Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN
February 1, 2024
Biotechnology
Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.
-
LabVantage Solutions and Biomax Informatics Merge
October 11, 2022
Software
LabVantage Solutions and Germany-based Biomax Informatics have closed a merger agreement to combine their laboratory informatics, knowledge-management and semantic-search capabilities. The combination brings together LabVantage’s LIMS/ELN/SDMS platform with Biomax’s decision-support and knowledge-management software to expand product and service offerings for life sciences, biomanufacturing and healthcare customers.
-
Keensight Capital Acquires Majority Stake in Bedfont Scientific Ltd.
October 13, 2025
Medical Devices
Keensight Capital has acquired a majority stake in Bedfont Scientific Ltd., a UK-based designer and manufacturer of non-invasive breath analysis medical devices. The investment will support Bedfont's international expansion, product innovation and potential M&A-driven growth while existing shareholders reinvest alongside Keensight.
-
Quanos Acquires Fischer Information Technology
August 2, 2024
Software
Quanos Group (backed by Keensight Capital) has acquired Fischer Information Technology GmbH, a German specialist in technical documentation and product information software. The add-on expands Quanos' aftersales and technical documentation product portfolio and strengthens its position as a global leader in AI-enabled industrial aftersales and technical documentation solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.